Microbix Biosystems Inc.MBX.TO

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · microbix.com

Microbix Biosystems Inc. is a Canadian life science company that develops and commercializes proprietary biological and technological solutions for human health and wellbeing. The company manufactures infectious disease antigens, external quality control materials (QAPs brand), viral transport medium (DxTM brand), and Kinlytic, a biologic thrombolytic drug used to treat blood clots, serving the global diagnostics industry. Headquartered in Mississauga, Canada, Microbix ships products to all seven continents.

Key ratios

Operating cash flow growth

-71.7%TTM

EPS growth

-62.7%TTM

FCF / Sales

-25.3%TTM

2025 -4.7%2024 10.7%2023 -12.8%

Net margin

-31.7%TTM

2025 -12.1%2024 13.9%2023 -0.2%

ROA

-7.4%TTM

2025 -2.6%2024 6.6%2023 -5.0%

ROE

-18.2%TTM

2025 -8.0%2024 13.3%2023 -0.2%

Revenue growth

-26.8%2025

2024 53.8%2023 -13.4%

Recent news

Microbix Reports Results for H1 & Q2 2026 2026-05-14 · Globe and Mail Microbix Product Results Being Presented at 2026 PASCV 2026-04-27 · BioSpace

Track MBX.TO in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer